Positron Emission Tomography (PET) to Study Brain Signaling
NCT00044200 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2018-07-05
Summary
This study uses positron emission tomography (PET) to examine brain function and signaling involving phospholipids, and to see how signaling is related to blood flow. Much of the brain is composed of fatty molecules called phospholipids. These molecules are involved in the way brain cells signal each other to direct brain function. Brain disease may change phospholipids and disturb brain structure and signaling. Studies of brain phospholipid composition and metabolism may help clarify how the brain works in healthy people or stops working effectively in disease states.
Healthy volunteers between 18 and 45 years of age may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood and urine tests. Participants undergo magnetic resonance imaging (MRI) and PET scanning as follows:
MRI
MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the subject lies on a table that is moved into a metal cylinder (the scanner) and wears earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. Scanning time varies from 20 minutes to 3 hours, with most scans lasting between 45 and 90 minutes. Subjects may be asked to lie still for up to 30 minutes at a time.
PET
For the PET scan, a catheter (thin plastic tube) is inserted into an artery in the subject's wrist or elbow crease to collect blood samples during the procedure, and a second catheter is placed in a vein in the opposite arm to inject radioactive tracers. The subject lies on the scanner bed, wearing a special facemask and goggles. The mask helps hold the head still during the scans, and the goggles either block all light or administer bright flashing lights. Radioactive water is injected into the vein, followed by a 1-minute PET scan to measure brain blood flow. This is repeated three more times. Then, a radioactive fatty acid is injected into the vein, followed by a 1-hour PET scan to measure brain phospholipid metabolism. This is repeated once. The images of blood flow and phospholipid metabolism in the different regions of the brain under the conditions of darkness and during visual stimulation provide information on how and where the brain responds to visual stimulation. The entire procedure takes about 3 hours.
Conditions
- Healthy
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Principal Investigators
-
Stanley I Rapoport, M.D. · National Institute on Aging (NIA)
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-01-10
- Completion
- 2015-06-12
Countries
- United States
Study Locations
More Related Trials
-
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram
NCT00250172 ·Status: COMPLETED ·Phase: PHASE1
-
[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598 ·Status: RECRUITING
-
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
NCT00613119 ·Status: COMPLETED
-
Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease
NCT04718207 ·Status: COMPLETED
-
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
NCT03958630 ·Status: TERMINATED ·Phase: PHASE1
-
Developing Advanced MRI Methods for Detecting the Impact of Nutrients on Infant Brain Development
NCT02058225 ·Status: COMPLETED
-
FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD
NCT04311281 ·Status: WITHDRAWN
-
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
NCT02676843 ·Status: COMPLETED ·Phase: PHASE2
-
Metabolic Abnormalities in Children With Epilepsy
NCT00001325 ·Status: COMPLETED
-
A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants
NCT05320302 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Imaging of Plaque Vulnerability
NCT02640313 ·Status: RECRUITING ·Phase: PHASE3
-
Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET
NCT04804722 ·Status: COMPLETED
-
PET Tau - Neurodegenerative Disease Imaging
NCT03143374 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
NCT02214862 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Changes in Alzheimer's Disease (AD)
NCT00094913 ·Status: UNKNOWN
-
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688 ·Status: RECRUITING ·Phase: PHASE3
-
Study of New Magnetic Resonance Imaging Methods of the Brain
NCT00004577 ·Status: RECRUITING
-
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Neuroinflammation Imaging in AD
NCT04274998 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Positron Emission Tomography of Amyloid in Alzheimer's Disease
NCT00205621 ·Status: SUSPENDED ·Phase: PHASE1
-
Imaging Tau Deposition in the Brain of Elderly Subjects
NCT02958670 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Magnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis
NCT04282317 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
NCT04786223 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia
NCT00966017 ·Status: UNKNOWN
-
Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease
NCT05582200 ·Status: RECRUITING